Zurich Cantonal Bank
ADAP

Zurich Cantonal Bank’s Adaptimmune Therapeutics ADAP Stock Holding History

Zurich Cantonal Bank’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-11,649
Closed -$64K – 2521
2017
Q1 		$64K Sell
11,649
-3,285
-22% -$14.4K ﹤0.01% 1611
2016
Q4 		$60K Sell
14,934
-102,300
-87% -$491K ﹤0.01% 1590
2016
Q3 		$826K Buy
117,234
+8,239
+8% +$62.8K 0.01% 805
2016
Q2 		$888K Buy
108,995
+3,519
+3% +$33.1K 0.01% 717
2016
Q1 		$858K Buy
+105,476
New +$863K 0.01% 735

Other funds holding ADAP

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Zurich Cantonal Bank's ADAP Position: Q2 2017 in Review

Zurich Cantonal Bank sold out of Adaptimmune Therapeutics (ADAP) in Q2 2017, closing a stake of 11,649 shares — an estimated $64K sold.

Zurich Cantonal Bank first reported a position in ADAP in Q1 2016 and held it in 5 quarters. The position peaked at $888K in Q2 2016. 56 funds tracked by Wall St. Rank hold ADAP as of Q2 2017.

  • Zurich Cantonal Bank reported no remaining Adaptimmune Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Zurich Cantonal Bank sold 11,649 Adaptimmune Therapeutics shares in Q2 2017, an estimated $64K.
  • Zurich Cantonal Bank first reported a position in Adaptimmune Therapeutics in Q1 2016 and held it in 5 quarters.
  • Zurich Cantonal Bank's Adaptimmune Therapeutics position peaked at $888K in Q2 2016.
  • 56 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2017.

Based on Zurich Cantonal Bank's 13F filing for Q2 2017, filed 8 Aug 2017.